RxSight, Inc. reported a strong start to 2022 with a 157% increase in revenue compared to the first quarter of 2021, driven by increased sales of Light Delivery Devices and Light Adjustable Lenses. The company has revised its 2022 full year revenue guidance to a range of $41.5 million to $45.5 million.
Delivered first quarter 2022 revenue of $8.9 million, a 157% increase compared to Q1 2021.
Sold 40 Light Delivery Devices (LDD™s), a 208% unit increase from Q1 2021.
Sold 4,166 Light Adjustable Lenses (LAL®s), a 166% increase in procedure volumes compared to Q1 2021.
Revised 2022 revenue guidance to a range of $41.5 million to $45.5 million.
RxSight revised its 2022 full year revenue guidance to a range of $41.5 million to $45.5 million. The company did not change its guidance for 2022 gross margin or operating expenses, which are ranges of 35% to 36% of revenue, and $86.0 million to $90.0 million, respectively.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance